At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 328 enrolled
Drug / intervention
armodafinil 150 mg +2 moredrug
Likely dose
armodafinil 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
In Brief
A Phase 3 clinical trial evaluating armodafinil 150 mg, Placebo, and 1 other intervention for Fatigue. Completed, enrolled 328 participants across 365 sites.
Detailed Summary
This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatigue
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartJun 2013
Primary CompletionMay 2019
Study CompletionDec 2019
TodayJul 2026
First PostedFeb 1, 2013
Enrollment StartJun 21, 2013
Primary CompletionMay 1, 2019
Study CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.4 years ago
Interventions
armodafinil 150 mgdrug
given orally
Placeboother
given orally
armodafinil 250 mgdrug
given orally